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BACKGROUND. Positron emission tomography (PET) with 18- ﬂuorodeoxyglucose
(FDG) has been used to both detect and stage a variety of malignancies. The
current study examined the value of PET for preoperative staging of gastric ade-
nocarcinoma.
METHODS. Sixty-eight patients (49 males and 19 females) with gastric adenocarci-
noma, who were referred for preoperative FDG-PET scans, were enrolled in this
study. The patients underwent spiral-computed tomography (CT) within 1 week of
referral. The ﬁnal diagnosis in all patients was made by histologic and surgical
ﬁndings. For quantitative PET analysis, the regional tumor FDG uptake was mea-
sured by the standardized uptake value (SUV).
RESULTS. For the primary tumor of a gastric adenocarcinoma, PET demonstrated
an increased uptake in 64 of 68 patients (sensitivity, 94%), with a mean SUV of 7.0
(range, 0.9–27.7). A comparison of FDG uptake and clinicopathologic features
showed signiﬁcant association between FDG uptake and macroscopic type, tumor
size, lymph node metastasis, histologic type, and TNM stage. The PET scan had a
similar accuracy with that of CT for diagnosing local and distant lymph node
metastases as well as peritoneal status. In assessing local lymph node status,
however, PET had a higher speciﬁcity than CT (92% vs. 62%, P  0.000). Moreover,
PET had additional diagnostic value in 10 (15%) of 68 patients by upstaging 4 (6%)
and downstaging 6 (9%) patients. PET combined with CT was more accurate for
preoperative staging than either modality alone (66% vs. 51%, 66% vs. 47%, re-
spectively; P  0.002).
CONCLUSIONS. FDG-PET improves the preoperative TNM staging of gastric ade-
nocarcinoma. Based on its superior speciﬁcity, FDG-PET can facilitate the selec-
tion of patients for a curative resection by conﬁrming a nodal status identiﬁed by
CT. Cancer 2005;103:2383–90. © 2005 American Cancer Society.
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Carcinoma of the stomach has a poor prognosis because manypatients have advanced disease at the time of diagnosis.1–3 There-
fore, pretreatment assessment and staging of disease is essential for
managing gastric carcinoma.4 The tumor stage provides the basis for
selecting the most appropriate therapeutic strategy.
Preoperative staging currently relies on a standard noninvasive
imaging modality of spiral-computed tomography (CT) of the abdo-
men and pelvis. However, CT is an anatomy-based diagnostic tech-
nique with certain drawbacks, including limited sensitivity from false-
negative ﬁndings due to nonenlarged invaded lymph nodes and
limited speciﬁcity from false-positive ﬁndings due to enlarged inﬂam-
matory lymph nodes. Therefore, a better preoperative evaluation
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strategy would greatly aid the preparation of treat-
ment plans for patients with gastric carcinoma.
Positron emission tomography (PET) using the
radiolabeled glucose analogue, 18F-ﬂuorodeoxyglu-
cose (FDG), as a tracer is a well established imaging
technique that offers new perspectives in staging ma-
lignant diseases. FDG-PET scanning enables observa-
tion of altered glucose metabolism in neoplastic cells.5
These images are complementary to traditional mor-
phologic images, such as those produced by CT, and
may be more sensitive because functional changes
often precede anatomic changes. Several studies have
conﬁrmed the added value of PET for detecting occult
metastases in patients with esophageal as well as head
and neck carcinomas.6,7 Flamen et al. reported that
PET improved staging in an esophageal carcinoma
with a speciﬁcity of lymph node staging.8
The TNM system is generally acknowledged as the
principal method for assessing extent of disease and
for determining the prognosis of gastric carcinoma
patients. The aim of the current study was to prospec-
tively assess the value of FDG-PET scanning for pre-
operative staging of gastric adenocarcinoma. In par-
ticular, this study aimed to assess and compare the




Sixty-eight patients with an esophagogastroduodenos-
copy biopsy-proven gastric adenocarcinoma, who
were referred between August 2000 and June 2003 to
the Department of Surgery of Yonsei University Col-
lege of Medicine for an evaluation of tumor resectabil-
ity, were enrolled in this study. The exclusion criteria
were previous gastric cancer treatment, diabetes mel-
litus, and inoperability for medical reasons. All pa-
tients underwent routine staging procedures, includ-
ing medical history and physical examination,
laboratory tests, upper gastrointestinal barium study,
and spiral CT of the abdomen and pelvis. In addition,
FDG-PET scanning was performed within the same
week.
Spiral CT of the Abdomen and Pelvis
CT scans with contiguous 7 mm slice thickness were
performed on all patients by a Somatom Plus-S (Sie-
mens, Munich, Germany), Tomoscan 310 (Philips,
Amsterdam, The Netherlands), or a LightSpeed Plus
(GE Healthcare, Waukesha, WI). The enhanced CT
scans were obtained after bolus intravenous injection
of a concentration of 60% wt/vol of iodine contrast
medium at a 2–4 mL/sec velocity with a volume of 2
mL/kg up to a maximum volume of 150 mL. Scans
were taken during a single breath hold.
Extent of the primary tumor, thickness of stomach
wall, tumor invasion of adjacent structures, and pres-
ence of a lesion suggesting metastasis to distant sites
were recorded. Lymph nodes (LN) measuring 10 mm
or more at their maximum cross-sectional diameter
were considered metastatic. An abdominal radiologist,
who was blinded to the FDG-PET ﬁndings, interpreted
all CT examinations prospectively.
FDG-PET
PET scans were performed using a PET scanner (GE
Advance, Milwaukee. WI) with an axial ﬁeld of view of
55 cm and a spatial resolution of 5 mm in the center of
the ﬁeld of view. All patients fasted for at least 4 hours
before the scan, and blood samples were taken imme-
diately before analyzing glucose level to conﬁrm pa-
tient normoglycemia. Transmission scans were ob-
tained in six bed positions, ranging from maxilla down
to proximal thighs. Thereafter, 370–555 Mbq of FDG
was injected into an antecubital vein, and the PET
imaging was begun after a 60-minute uptake period.
The emission scan was obtained in 6 bed positions (5
min in each bed position), using the same sequence
and range as transmission scans. All images were cor-
rected for delay and photon attenuation and were
reconstructed in a 128  128 matrix using an iterative
reconstruction algorithm with 32 iterations. The FDG
activity within each tumor was corrected for its phys-
ical decay and was normalized by the administered
dose as well as the patients’ weight to produce a
Standardized Uptake Value (SUV), using a 3-point
scale, ranging from 1 (normal), 2 (equivocal), to 3
(abnormal). For this analysis, scores of 2 and 3 were
considered positive. SUVs of abnormal sites were also
recorded as follows: SUV  (activity per cc)  (in-
jected activity per grams of body weight). In determin-
ing the SUV, a region of interest was drawn around the
lesion, and the maximum activity was used to mini-
mize the inter- and intra-observer variability. Image
processing and reconstruction were performed using
a high-resolution display monitor (SUN workstation;
Sun Microsystems, Mountain View, CA). Two experi-
enced nuclear medicine physicians evaluated all PET
images, and there was 100% agreement between
them. The preliminary PET interpretation was per-
formed without prior knowledge of patient history
including CT ﬁndings. PET images were compared
using CT images for the ﬁnal interpretation, and pa-
tient management was based on a combined interpre-
tation.
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Patient Management
Discordant PET data affecting the patient staging
and/or management were considered only if they
were conﬁrmed by histology or by dedicated radio-
graphic techniques. All staging was assigned using the
guidelines from the 5th American Joint Committee on
Cancer (AJCC) TNM staging guidelines.4 The treat-
ment represented a consensus individualized for each
patient.
Surgery
Standardized surgical procedures were performed as
follows: 1) a total or distal subtotal gastrectomy de-
pending on the location and the macroscopic type of
the gastric cancer; 2) a D2 or D3 lymphadenectomy. A
lymph node dissection was classiﬁed according to
rules set down by the Japanese Research Society for
Gastric Cancer (JRSGC).9 The deﬁnitions of a D2 and
D3 lymphadenectomy are as follows: Regional lymph
nodes of the stomach were classiﬁed into four com-
partments according to rules from the JRSGC. Com-
partment I consisted of the perigastric lymph nodes.
Compartment II consisted of the lymph nodes along
the left gastric artery, along the common hepatic ar-
tery, around the celiac axis, and along the splenic
artery. Compartment III consisted of lymph nodes in
the hepatoduodenal ligament, at the posterior aspect
of the head of the pancreas, and at the root of the
mesentery. Lymph nodes along the splenic artery were
classiﬁed as being in Compartment III when the can-
cer was located in the lower third of the stomach.
Compartment IV consisted of lymph nodes along the
middle colic vessels and the paraaortic lymph nodes.
The anatomic level of a D2 lymphadenectomy in-
cluded a complete dissection of Compartments I and
II, whereas a D3 lymphadenectomy included those of
Compartments I, II, and III. In this study, Compart-
ment I or II was classiﬁed in the local lymph node
group, whereas Compartment III or IV was classiﬁed
in the distant lymph node group. 3) A gastrectomy
with an additional organ resection was performed to
either facilitate a more extensive lymph node dissec-
tion or to gain a complete tumor resection. 4) A gas-
trectomy was not performed on those who had a dis-
tant metastasis including a multiple peritoneal
dissemination, multiple liver metastatic lesions and
local far advanced disease, and those patients usually
undergoing a bypass without a resection or an explor-
atory (nontherapeutic) laparotomy with a node bi-
opsy.
The level of the dissected lymph nodes from ex-
cised specimens were veriﬁed by surgeons, and all
retrieved lymph nodes were examined for a metastasis
by optical microscopy after being stained with hema-
toxylin and eosin. The histologic classiﬁcation of a
gastric cancer was determined according to the JRSGC
classiﬁcation.
Data Analysis
Imaging results were compared using the gold stan-
dard provided by a histologic examination of routine
hematoxylin-eosin–stained sections of the tissue ob-
tained from a gastrectomy in 61 patients, an explor-
atory (nontherapeutic) laparotomy with a perigastric
LN biopsy in 4 patients, and a laparotomy bypass with
a perigastric LN biopsy in 3 patients.
The gold standard for T stage was exclusively de-
ﬁned by histology. Therefore, it was only available in
the subgroup of patients in whom either a curative or
palliative gastrectomy had been performed. To assess
involvement of lymph nodes, the gold standard was
exclusively deﬁned by a histologic examination of tis-
sue obtained in patients in whom either a D2 or D3
lymphadenectomy or a perigastric LN biopsy had
been performed.
For analysis of the accuracy of the combined use
of FDG-PET and CT, the positive results of both tech-
niques were cumulated. Therefore, a positive result
with one technique overruled a negative result with
the other.
Statistics
The statistical software package for social science
(SPSS) version 10.0 for Windows (SPSS. Inc, Chicago,
IL) was used for all statistical analyses. The relation
between FDG uptake and other parameters was deter-
mined using the one-way ANOVA method. A simple
regression analysis was used to determine the relation
between FDG uptake and tumor size. The sensitivity,
speciﬁcity, and accuracy of CT and FDG-PET imaging
modalities were estimated using the standard deﬁni-
tion.10 A chi-square test, a McNemar test, and a Fisher
exact test were used to examine signiﬁcance of corre-
lated proportions between the FDG-PET and CT ﬁnd-
ings. A P value of  0.05 was considered signiﬁcant.
RESULTS
Patient Characteristics
Of the 68 patients in this study, there were 19 women
and 49 men with a mean age of 54.8 years (range
28–81yrs). Eight patients had early gastric cancer
(EGC), and 60 had advanced gastric cancer (AGC) with
a mean tumor size of 6.8 cm. Tumor penetration of the
serosa (T3) was the most common type of invasion (50
of 68 patients, 73.5%). There were 47 patients with
local LN metastases, and 8 patients with distant LN
metastases. A histologic diagnosis of a differentiated
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adenocarcinoma was made in 13 patients, and the
other 55 were diagnosed with an undifferentiated ad-
enocarcinoma. Two patients had hematogenic metas-
tases (1 liver, 1 spleen). Ten patients had documented
peritoneal dissemination. According to the 5th AJCC
TNM classiﬁcation, there were 10 patients with Stage I
disease, 4 patients with Stage II disease, 29 patients
with Stage III disease, and 25 patients with Stage IV
disease. Fifty-eight patients underwent a curative gas-
trectomy with a D2 or D3 lymphadenectomy, and 3
patients underwent a palliative gastrectomy with a D2
lymphadenectomy. Four patients underwent explor-
atory (nontherapeutic) laparotomy with perigastric
lymph node biopsy, and another three patients re-
ceived bypass surgery with a perigastric lymph node
biopsy (Table 1).
Primary Tumor Assessment
FDG-PET demonstrated increased activity in the pri-
mary gastric adenocarcinoma in 64 of the 68 patients
(sensitivity, 94%), with a mean SUV of 7.0 (range,
0.9–27.7). Figure 1 shows a typical FDG-PET scan of a
patient with gastric adenocarcinoma. The scan shows
intense uptake in the stomach and another area of
intense uptake (lymph node metastasis) in the peri-
gastric lesion. False-negative (FN) PET images were
obtained from 4 patients, 3 were pT1 lesions, (all of
which were conﬁned to the mucosa with a diameter
 3 cm), and 1 was a pT3 lesion (the diameter was 4
cm, gross type, Borrmann 3, signet ring cell adenocar-
cinoma). When assessed by quantitative analysis, the
mean SUV was higher in AGC (7.5) than in EGC (2.1) (P
 0.016) (Table 2). There was a signiﬁcant difference
in PET sensitivity in detecting a primary AGC and an
EGC (98% vs. 63%, P  0.004). The mean SUV was
higher in the tubular adenocarcinoma group than in
the mucinous and signet ring cell adenocarcinoma
(SRC) group (7.7 vs. 4.2, P  0.043) (Table 2). The
sensitivity of the CT scan for diagnosing a primary
tumor was 93% (63 of 68 patients). The CT scan failed
to detect a primary tumor in three patients (two pT1
mucosa lesions; one pT3 poorly differentiated adeno-
carcinoma). The CT scan misdiagnosed two early gas-
tric cancer patients by upstaging them to advanced
gastric cancer. The sensitivity of PET and CT imaging
in diagnosing a primary tumor was similar (94% vs.
93% P  0.164). We also found signiﬁcant correlation
between tumor size and SUV (Fig. 2).
Diagnosis of LN Metastasis
Sixty-one (90%) of the 68 patients underwent a D2 or
D3 lymphadenectomy in conjunction with a primary
gastrectomy (58 curative resection, 3 palliative resec-
tion). The histologic diagnoses were as follows: No LN
involvement in 13 (19%) patients, local LN involve-
ment in 47 (69%) patients, and distant LN involvement
in 8 patients. Seven (12%) patients were unavailable
for a distant LN histologic diagnosis for those who did
not undergo a lymphadenectomy (Table 1). Patients
with lymph node metastasis (N1–3) had a higher SUV
than that of the N0 group (P  0.034) (Table 2).
Table 3 gives an overview of calculated sensitivi-
ties, speciﬁcities, and accuracy of the imaging modal-
ities for diagnosing LN involvement in this study
group. In detecting a local LN, the sensitivity of PET
was lower than that of CT (56% vs. 78% P 0.002), but
TABLE 1
Clinicopathologic Features of Gastric Adenocarcinomas
Parameter
No.
(n  68) %

























Tubular adenocarcinoma 56 82






Hematogenic metastasis 2 3




EGC: early gastric cancer, AGC: advanced gastric cancer, L-LN: local lymph node, D-LN: distant lymph
node, SRC: signet ring cell adenocarcinoma.
a Data was unavailable in 7 patients because they did not undergo gastrectomy and lymphadenectomy.
b According to the 5th AJCC classiﬁcation.
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the speciﬁcity was higher (92% vs. 62% P  0.000).
However, overall accuracy of PET in detecting both
local and distant LN metastasis was not signiﬁcantly
different from that of CT.
Detection of Hematogenic Metastasis and Peritoneal
Dissemination
Two (3%, 2 of 68)patients had a hematogenic metas-
tasis that was conﬁrmed by histology after surgery (1
liver, 1 spleen). PET showed a false negative in the
liver metastasis lesion and a true positive in the spleen
metastasis lesion. CT showed false-negative results in
spleen metastasis lesions, and a true-positives in liver
lesions. The false-positive ﬁndings from PET and CT
were all found in liver lesions (3 patients vs. 2 patients,
respectively), of which there was no evidence that
these lesions were found during surgery and no fur-
ther manifestation was noted during followup.
In the situation of a peritoneal dissemination, a
FIGURE 1. Primary adenocarcinoma of stomach with local lymph node
involvement. (A) Coronal PET scan demonstrates a primary tumor (T arrow) and
a local lymph node (LN arrow) with increased FDG uptake. (B) Axial PET scan
and CT scan demonstrate a primary tumor and a local lymph node (arrows).
TABLE 2






(mean) F P valuea
Macroscopic type
EGC 8 2.1 6.142 0.016
AGC 60 7.5
Histologic type
Tubular 56 7.7 4.290 0.043
Mucinous/SRC 12 4.2
LN metastasisb





Positive 10 6.8 0.021 0.887
Negative 58 7.0
Stage
I or II 14 3.7 6.504 0.013
II or IV 54 5.4
EGC: early gastric cancer, AGC: advanced gastric cancer, LN: lymph node, SRC: signet ring cell
adenocarcinoma.
a The results were using the analysis of one-way ANOVA method; P  0.05 was considered signiﬁcant.
b Data were unavailable for 7 patients because they did not undergo gastrectomy and lymphadenec-
tomy. LN metastasis and stage classiﬁcation were according to the 5th AJCC classiﬁcation.
FIGURE 2. Relation between FDG uptake (standardized uptake value, SUV)
and longitudinal diameter of primary tumor. Y 1.892 0.791X; R2 0.176;
F  10.910; P  0.002.
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total of 10 (15%, 10 of 68)patients were diagnosed with
peritoneal dissemination based on a surgical and his-
tologic conﬁrmation. The mean SUV shows no signif-
icant difference in peritoneal dissemination (Table 2).
Both PET and CT had a high accuracy for diagnosing a
peritoneal dissemination (88% vs. 89% P  not signif-
icant) (Table 3). CT showed a higher sensitivity com-
pared with PET (80% vs. 30%), but it did not reach
statistical signiﬁcance (P  0.063).
Improvement in Preoperative Staging with FDG-PET
For TNM staging according to FDG uptake, the mean
SUV was higher in Stages III and IV than in Stages I
and II (5.4 vs. 3.7, P  0.013) (Table 2).
Overall, the accuracy of preoperative staging using
PET, CT, and PET combined with CT was 47% (32 of 68
patients), 53% (36 of 68 patients), and 68% (46 of
68patients), respectively, (P  0.002) (Table 4). PET
combined with CT had signiﬁcantly higher accuracy in
preoperative staging than PET or CT alone. PET
tended to understage (44%, 30 of 68 patients), whereas
CT tended to overstage (24%, 16 of 68 patients). For
example, PET upstaged 4 patients (6%, 4 of 68 pa-
tients) from the CT staging (1 spleen metastasis lesion,
1 distant LN, 1 local LN, and 1 primary lesion), and
downstaged 6 (9%, 6 of 68) patients from CT staging (2
peritoneal dissemination, 3 distant LN, and 1 liver
metastasis). The additional value of PET preoperative
staging was found to be 15% (10 of 68 patients).
DISCUSSION
Accurate pretreatment staging in gastric cancer is ex-
tremely important for providing information on po-
tential curability as well as for planning an optimal
therapeutic strategy.5 The mainstay of clinical staging
is still based on the CT scan, but the accuracy of CT
alone for making an optimal preoperative diagnosis
remains to be conﬁrmed.11–14 CT has major limita-
tions in assessing LN metastasis, in identifying perito-
neal dissemination, and in identifying small hemato-
genic metastases. Recently, tissue metabolism based
FDG-PET has emerged as a promising new modality
for tumor staging. The limited published experience
with esophageal and gastric carcinomas suggests that
FDG-PET is highly sensitive in detecting the primary
tumor as well as distant metastases. The high sensi-
tivity of PET in detecting the primary adenocarcinoma
of the stomach was conﬁrmed in this prospective
study, which is consistent with several other re-
ports.15–17
We observed several interesting results concern-
ing the use of FDG-PET in detection of primary tumor.
First, FDG uptake and sensitivity of PET for detecting
primary tumor in early gastric cancer and in advanced
gastric cancer were signiﬁcantly different (P  0.05).
Second, we found a signiﬁcant relation between SUV
and primary tumor size. These results suggested that
FDG uptake could be closely associated with tumor
progression in gastric adenocarcinoma. Third, the
mean SUV was higher in the tubular adenocarcinoma
group than in the mucinous and signet ring cell ade-
nocarcinoma group. This result has been demon-
strated by several other reports.18–20 It has been pos-
tulated that the low or absent FDG avidity in SRC
resulted from the high content of metabolically inert
mucus leading to a reduced FDG concentration. An-
other reason could be the lack of expression of the
glucose transporter Glut-1 on the cell membrane of
most SRC and mucinous adenocarcinoma.21
We found a signiﬁcant difference between the
primary tumor SUV and the extension of lymph node
metastasis. Increased SUV of primary tumor always
TABLE 3
Preoperative Assessment of Lymph Node and Peritoneal Metastases
PET (%) CT (%) P valuea
Sensitivity
L-LN 31 of 55 (56) 43 of 55 (78) 0.002
D-LN 7 of 8 (88) 6 of 8 (75) 1.000
Peritoneum 3 of 10 (30) 8 of 10 (80) 0.063
Speciﬁcity
L-LN 12 of 13 (92) 8 of 13 (62) 0.000
D-LN 51 of 53 (96) 48 of 53 (91) 0.219
Peritoneum 57 of 58 (98) 53 of 58 (91) 0.125
Accuracy
L-LN 43 of 68 (63) 51 of 68 (75) 0.115
D-LNb 58 of 61 (95) 54 of 61 (89) 0.180
Peritoneum 60 of 68 (88) 61 of 68 (89) 1.000
L-LN: local lymph node, D-LN: distant lymph node.
a Results were compared by MacNemar test for correlated proportions; P  0.05 was considered
signiﬁcant.
b Data were unavailable for 7 patients because they did not undergo gastrectomy and lymphadenec-
tomy.
TABLE 4
Overall Accuracy of Preoperative Staging in Patients with Gastric
Adenocarcinoma
Correct False
P valuean % n %
PET 32 47 36 53 0.002
CT 36 53 32 47
PET  CTb 46 68 22 32
a Results were compared by Chi-square test; P  0.05 was considered signiﬁcant.
b Correct results of both techniques were cumulated. Therefore, a correct result with one technique
overruled a false result with the other.
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correlated with lymph node metastasis, which was
also observed by Mochikis et al.17 FDG uptake is be-
lieved to be carried out by glucose transporters
(Gluts), a signiﬁcant increase in Glut-1 mRNA and
protein has been described in tumors of the esopha-
gus, stomach, and colon.21–23 Positive correlations be-
tween Glut-1 expression and an increased incidence
of lymph node metastasis in patients with colorectal
and gastric carcinoma have been described.21,23 Thus,
increased FDG uptake in a primary tumor may be an
indication of an increased risk of lymph node metas-
tasis.
For an assessment of a local LN involvement,
FDG-PET had a signiﬁcantly higher speciﬁcity than CT
(92% vs. 62%, P  0.000) and a signiﬁcantly lower
sensitivity (56% vs. 78%, P  0.002), although the
overall accuracy of both modalities was similar (63%
vs. 75%, P  0.115). The lower sensitivity of FDG-PET
for detecting a local LN was attributed to the limited
spatial resolution of the PET scanner. Therefore, the
low focal uptake of a local LN may not be separated
from the primary lesion, which has intense tracer ac-
cumulation and ill-deﬁned anatomical boundaries.6
The limitation in detecting a local LN has been re-
ported in that PET could not reliably distinguish be-
tween N0 and N1 disease.8 However, it would not pose
a potential management problem because a D2 resec-
tion (the removal of the N1 and N2 nodes with the
primary tumor) is a routine procedure at our institute.
In contrast to the report by Yeung et al.,16 which
suggested that a lymph node distant from the stomach
would theoretically be easier to identify on a FDG-PET
scan, our study failed to show the advantage of FDG-
PET for detecting distant LN metastasis compared to
the CT scan. Although ﬁve false-positive and two false-
negative results were noted in the CT scan results and
only two false positive and one false negative in the
PET results, this difference was not statistically signif-
icant. PET was able to correct the stage in four patients
who had been inaccurately staged by CT preopera-
tively.
In patients with a peritoneal dissemination, FDG-
PET had a strong tendency of low sensitivity com-
pared with CT scan (P  0.063). Although it is not
statistically signiﬁcant, this is in line with reports by
Herrington et al.,15 Yeung et al.,16 and Jadvar et al.24
False-negatives were found in 7 of 10 patients. From
surgical observations, all these patients had small ( 5
mm) nodules of peritoneal seeding. The pathology
showed mainly extensive ﬁbrosis with a small number
of malignant cells in the disseminated lesion. The
actual tumor cells were too sparse and spread out to
provide sufﬁcient information for the PET scanner to
detect. Although CT has a high sensitivity in detecting
a peritoneal dissemination, it has a low speciﬁcity due
to high false-positive ﬁndings. When detecting perito-
neal carcinomatosis, CT can easily detect abnormal
abdominal changes based on signs such as peritoneal
caking, nodularity, beaded thickening, and malignant
ascites.25,26 Given that a positive diagnosis of these
ﬁndings may lead to a false-positive result, laparos-
copy was recently used to conﬁrm the positive ﬁnd-
ings by CT. This is because this minimally invasive
staging modality is quite sensitive in detecting small
volume peritoneal metastases.14 Distant metastasis is
uncommon, but its detection is important when mak-
ing a preoperative evaluation. Unfortunately, both
FDG-PET and CT missed one hematogenic metastasis
and produced false-positive results in a liver metasta-
sis. Although the number was small, this suggests that
neither an FDG-PET nor a CT scan alone is useful for
detecting small hematogenic metastases. To reduce
the incidence of unnecessary surgery, laparoscopic
ultrasonography could be recommended.
Normal stomach may also demonstrate FDG up-
take. In our experience, the uptake level is low and
usually conforms to gastric conﬁguration, and few of
them have 2 points in our 3-point scale. Only Grades
2 and 3 were considered as positive to be included in
this study in order to decrease the possibility of false
positive results.
When interpreting the results of PET, one should
consider that a false-positive diagnosis may prevent it
from being safely applied. In our patients, PET over-
staged one patient due to the false-positive FDG ac-
cumulation in the inﬂammatory local LN and liver
(with cholecystitis). Another ﬁve false-positive diag-
noses were made in the case of two distant LNs, one
peritoneal dissemination, and two liver lesions. There-
fore, despite its high positive predictive value, it is
important to conﬁrm the malignant nature of the le-
sion found by PET. This may lead to change in thera-
peutic management.
Based on these results, PET may play a comple-
mentary role in pretreatment evaluation. FDG-PET
upstaged 4 (6%) patients from the false-negative CT
ﬁndings. PET provided important information for
making decisions regarding treatment. A splenectomy
was performed in a patient who was later conﬁrmed to
have a spleen metastasis, and a D4 lymphadenectomy
was performed in a patient who was later conﬁrmed to
have a No. 16, and No. 111 LN metastasis. FDG-PET
downstaged 6 (9%) patients from CT false-positive
ﬁndings. Therefore, those patients who beneﬁted from
the FDG-PET detection method were treated with a
timely curative resection, without the need for any
extra neoadjuvant chemotherapy.
In conclusion, FDG-PET appears to be a prospec-
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tive method for making a preoperative evaluation of
gastric adenocarcinoma. PET can provide important
additional information concerning the preoperative
staging of gastric adenocarcinoma. FDG-PET and CT
are expected to play complementary roles, and to-
gether they should be able to increase the accuracy of
preoperative staging. A further study on modifying the
spatial resolution using radiotracers is needed to im-
prove the sensitivity of local LN involvement and peri-
toneal dissemination and to fully integrate FDG-PET
into routine staging of a gastric adenocarcinoma.
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